The University of Toronto and McMaster University are joining forces to launch a new $40-million venture capital fund, marking a significant shift in the way Canadian universities approach their spinouts. This initiative, managed by Toronto-based Genesys Capital, is a bold move to address a long-standing issue: the underutilization of Canadian research and its economic impact. The fund's primary focus is on life sciences startups, particularly those stemming from the two universities, with a strong emphasis on medical devices and drugs targeting cancer and cardiovascular diseases.
This move is a strategic response to the underinvestment in Canadian life sciences venture capital by institutional investors. The fund's creation is a direct challenge to the status quo, as it aims to bridge the gap between groundbreaking research and its commercial realization. The universities are investing in this fund with revenues from their technology transfer offices, which license patents for commercial use, indicating a commitment to turning intellectual property into financial success.
The initiative is not an isolated case. It is part of a growing trend among Canadian universities to support their academics in entrepreneurship. The University of Calgary, McGill University, and the University of Waterloo have all launched similar seed funds to finance their spinouts. This shift is a response to the realization that while Canadian researchers have made significant discoveries, such as insulin and stem cells, the economic benefits have often been realized elsewhere.
The Genesys fund is particularly notable for its strong track record in venture capital. Genesys has already raised more than half of its target and has a history of big returns, with two of its drug companies selling for 10-figure sums in 2023 and 2024. This success is a testament to the fund's ability to identify and nurture promising life sciences startups. The partnership with McMaster University further strengthens the fund's potential, as it brings a diverse deal flow and a broader network of opportunities.
The fund's creation is a significant step towards a more self-sufficient and innovative Canada. It represents a shift in the way universities approach their research, with a focus on turning intellectual property into tangible economic benefits. The involvement of the Ontario government and other major investors further underscores the importance of this initiative and its potential to drive economic growth and innovation in Canada's life sciences sector.
